pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›JASCAYD
drug
save

JASCAYD

updated 6mo ago
by Boehringer Ingelheim Corp
community read0 votes

🐶 often sniffed alongside

top 4
  • drugnerandomilast12 co-mentions · 3 sources
  • tagApproval12 co-mentions · 3 sources
  • companyBoehringer Ingelheim Corp6 co-mentions · 3 sources
  • tagSmall Molecule6 co-mentions · 3 sources

all catalysts(0)

nothing on the calendar yet

Trials studying JASCAYD

  • phase3A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathiesnot yet recruitingn=270
  • phase3A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosisrecruitingn=80
  • phase3A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)recruitingn=35
  • phase3A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosisrecruitingn=448
  • phase3FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progressionrecruitingn=466
  • phase3A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseasesactive not recruitingn=413
  • phase3A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilastactive not recruitingn=1,666
  • phase2Platform Clinical Study for Conquering Sclerodermarecruitingn=400

News(6)

  • Bristol Myers dips on ‘confounding’ lung drug results
    Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.
    biopharma_dive · 1mo ago
  • BMS reports liver injury events in lung disease program, with key readout near
    Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…
    biospace · 1mo ago
  • Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
    BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
    biospace · 2mo ago
  • How well are AI-discovered drugs faring in the clinic?
    Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.
    biopharma_dive · 4mo ago
  • A PureTech startup banks $180M for a new IPF drug
    Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
    biopharma_dive · 4mo ago
  • Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
    The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.
    biopharma_dive · 6mo ago
brand
JASCAYD
generic
NERANDOMILAST
Data sources
ClinicalTrials.gov
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?